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httpcense.Abstract Introduction: Glucocorticoid induced down-regulation of systemic inﬂammation in
ARDS is associated with a signiﬁcant improvement in pulmonary and extrapulmonary organ dys-
function and a reduction in duration of mechanical ventilation and ICU length of stay [1].
We aimed in this study to evaluate the effect of methyl prednisolone when used early in ARDS.
Patients and methods: We studied 27 patients with ARDS, we divided them randomly into two
groups the ﬁrst group consists of 18 patients received methyl prednisolone and the other group con-
sists of 9 patients did not receive it. All patients were subjected daily to: history taking and clinical
examination, Chest X-ray, routine blood investigation (CBC–LFT–RFT–electrolytes), ABG,
Serum lactate, INR, ﬁbrinogen, and aptt, CRP, protein C, protein S, and D-dimer at the beginning
and at the end of study.
Results: After 7 days there were signiﬁcant improvements of clinical parameters (pulse, temper-
ature, and systolic blood pressure), peep (one parameter from lung injury score), lactate, D-dimer,
AST, and a highly signiﬁcant improvement of creatinine in the methyl prednisolone group when
compared to the control group. After 14 days from starting treatment there were signiﬁcant
improvements of clinical parameters (pulse and systolic BP), ventilator parameters (FIO2, peep,distress syndrome; LIS, lung
R, international normalized
ALT, alanine aminotransfer-
CRP, C reactive protein; RR,
expiratory pressure; FIO2,
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168 N. Abdelsalam Rezk, A. Mohamed Ibrahimand RR), systemic inﬂammation markers organ functions (O2sat, lactate, creatinine, WBCs, AST,
and GGT) and CRP. And a signiﬁcant improvement of CX-ray, earlier extubation from mechanical
ventilation and improvement of mortality in the methyl prednisolone group when compared with
the control group.
Conclusion: We conclude that methyl prednisolone when used on ﬁrst 2 days in ARDS patients
improves the LIS, decreases the systemic inﬂammation, earlier extubation from mechanical ventila-
tion, and decreases the incidence of hospital acquired infection.
ª 2013 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.Introduction
In ARDS, the evolution of systemic and pulmonary inﬂamma-
tion in the ﬁrst week of mechanical ventilation determines the
physiologic progression (resolving vs. unresolving) and out-
come of the disease [2].
The lung injury score (LIS) quantiﬁes the physiologic respi-
ratory impairment in ARDS through the use of a 4-point score
based on the levels of positive end-expiratory pressure (PEEP),
ratios of PaO2 to fraction of inspired oxygen (FIO2), the static
lung compliance, and the degree of inﬁltration present on chest
radiograph [9].
Patients failing to improve the LIS or its components by
day 7 of ARDS (unresolving ARDS), contrary to improvers,
have persistent elevation in circulating and BAL levels of
inﬂammatory cytokines and chemokines, markers of alveolo-
capillary membrane permeability [5] and ﬁbrogenesis (dysregu-
lated systemic inﬂammation) [3], and a higher mortality [4].
Glucocorticoid induced down-regulation of systemic
inﬂammation in ARDS is associated with a signiﬁcant
improvement in pulmonary and extrapulmonary organ dys-
function and a reduction in duration of mechanical ventilation
and ICU length of stay. [1]
We aimed in this study to evaluate the effect of methyl
prednisolone in early ARDS regarded to outcome, incidence
of infection, organ dysfunction, D-dimer, CRP, protein C
and protein S.
Patients and methods
This study was performed in Farwaneya Hospital Kuwait
October 2011–October 2012 in ICU department, we divided
the 27 patients with ARDS randomly into two groups the ﬁrst
group consists of 18 patients received methyl prednisolone and
the other group consists of 9 patients received normal saline in
the same manner of methyl prednisolone.
Inclusion criteria
(1) All patients must get criteria of ARDS.
(2) All patients must be on mechanical ventilation.
(3) Methyl prednisolone must be started randomly in ﬁrst
48 h.Exclusion criteria
(1) PaO2/FIO2 more than 200
(2) Patients were not on mechanical ventilation.All patients were subjected daily to:
(1) History taking and clinical examination.
(2) Chest X-ray daily, and we divided it into 4 quadrants.
(3) Routine blood investigation (CBC–LFT–RFT–
electrolytes).
(4) ABG.
(5) Serum lactate, INR, ﬁbrinogen, and aptt.
(6) CRP, protein C, protein S, and D-dimer at the begin-
ning and at the end of study.
Methyl prednisolone dosing [1]
Methylprednisolone was mixed in 240 mL of normal saline
solution and administered daily as an infusion at 10 mL/h
and changed to a single oral dose when enteral intake was re-
stored. A loading dose of 1 mg/kg was followed by an infusion
of 1 mg/kg/d from day 1 to day 14, 0.5 mg/kg/d from day 15 to
day 21, 0.25 mg/kg/d from day 22 to day 25, and 0.125 mg/kg/
d from day 26 to day 28. If the patient was extubated between
days 1 and 14, the patient was advanced to day 15 of drug ther-
apy and tapered according to schedule.
ARDS criteria (Bernard et al. 1994)
(1) PaO2/FIO2 less than 200
(2) Bilateral pulmonary inﬁltrates
(3) PAWP less than 18 mmHg
* Data was analyzed using SPSS (Statistical Package for
Social Sciences) version 15. Qualitative data was presented as
number and percent. Comparison between groups was done
by Chi-Square test. Data was presented as mean ± SD. Paired
t-test was used for comparison within groups. Student t-test
was used to compare between two groups. P < 0.05 was con-
sidered to be statistically signiﬁcant.
Results
There were no signiﬁcance difference between the methyl pred-
nisolone and control groups in all parameters except peep, ps,
and ﬁbrinogen were signiﬁcantly higher in the methyl prednis-
olone group when compared with the control group before
starting of methyl prednisolone. O2sat, PaO2, pCO2, HB,
and creatinine were higher in the control group when com-
pared with the methyl prednisolone group in the same time
(see Table 1).
There were signiﬁcant improvements of pulse, temperature,
systolic blood pressure, peep, lactate, D-dimer, creatinine, and
Table 1 Demographic data, clinical data, ventilator param-
eters, ABG, biochemical examination and chest X-ray in
methyl prednisolone group and control group in the ﬁrst day
of study.
Cases (n= 18) Control (n= 9) P value
42.67 ± 13.95 50.44 ± 13.99 0.185
Sex
Male 16 (88.9%) 7 (77.8%) 0.444
Female 2 (11.1%) 2 (22.2%)
Cause
HAP 6 (33.3%) 5 (55.6%) 0.541
CAP 6 (33.3%) 2 (22.2%)
Trauma 6 (33.3%) 2 (22.2%)
Comorbid
0 6 (33.3%) 2 (22.2%) 0.440
1 6 (33.3%) 4 (44.1%)
2 0 (0%) 1 (11.1%)
3 6 (33.3%) 2 (22.2%)
CXR-before 3.67 ± 0.49 3.11 ± 0.93 0.122
Pulse 104.33 ± 17.99 120.89 ± 20.00 0.039
Temperature 37.92 ± 0.75 38.53 ± 0.88 0.069
Systolic BP 127.50 ± 17.64 120.00 ± 20.62 0.334
Diastolic BP 67.00 ± 6.70 69.78 ± 12.10 0.446
FIO2 91.67 ± 12.49 77.78 ± 22.79 0.118
PEEP 11.00 ± 3.14 8.44 ± 2.55 0.045
PS 15.83 ± 1.92 13.33 ± 2.50 0.008
O2sat 95.17 ± 2.75 97.78 ± 2.54 0.025
PaO2 70.33 ± 10.23 91.33 ± 19.30 0.012
PaCO2 31.05 ± 18.72 43.89 ± 6.43 0.015
PH 7.32 ± 0.03 7.18 ± 0.23 0.115
INR 1.37 ± 0.13 1.46 ± 0.43 0.562
Lactate 3.40 ± 2.11 2.24 ± 1.34 0.148
APTT 34.67 ± 4.89 36.18 ± 4.56 0.447
WBCs 18.32 ± 2.68 17.60 ± 6.65 0.763
HB 90.33 ± 19.39 113.78 ± 18.69 0.006
Platelet 178.00 ± 106.19 224.89 ± 130.16 0.325
D-dimer 508.89 ± 100.99 444.44 ± 84.57 0.113
Na 140.17 ± 5.77 138.56 ± 3.81 0.457
K 3.92 ± 0.81 3.92 ± 1.34 0.991
Creatinine 98.33 ± 54.29 171.56 ± 52.26 0.003
Bilirubin 35.12 ± 9.07 29.60 ± 19.39 0.437
AST 46.83 ± 31.83 225.44 ± 219.67 0.041
ALT 73.17 ± 27.77 100.89 ± 79.21 0.335
GGT 90.33 ± 58.62 185.33 ± 217.77 0.232
Albumin 27.00 ± 8.63 27.44 ± 5.70 0.890
Fibrinogen 9.20 ± 1.97 7.09 ± 2.95 0.036
CRP 240.67 ± 98.87 216.67 ± 186.51 0.725
Protein C 100.28 ± 14.80 109.22 ± 17.48 0.175
‘protein S 114.89 ± 18.79 120.00 ± 20.15 0.521
Table 2 Clinical data, ventilator parameters, ABG, biochem-
ical examination and chest X-ray in methyl prednisolone group
and control group in 7th day of study.
Cases (n= 18) Control (n= 9) P value
Pulse 92.50 ± 14.86 113.11 ± 4.26 0.000
Temperature 37.13 ± 0.62 37.89 ± 0.33 0.002
Systolic BP 148.17 ± 14.99 122.22 ± 13.02 0.000
Diastolic BP 71.00 ± 13.38 65.56 ± 6.82 0.174
FIO2 65.00 ± 11.50 64.44 ± 15.09 0.916
PEEP 8.67 ± 1.85 10.22 ± 1.20 0.031
RR 14.83 ± 1.72 16.44 ± 1.67 0.029
PS 14.17 ± 1.92 13.78 ± 1.92 0.624
O2sat 97.67 ± 1.85 99.11 ± 1.76 0.063
PaO2 84.50 ± 9.08 83.78 ± 11.14 0.858
PaCO2 27.35 ± 16.26 49.22 ± 6.30 0.000
PH 7.35 ± 0.01 7.31 ± 0.07 0.141
INR 1.20 ± 0.10 1.39 ± 0.27 0.074
Lactate 1.78 ± 0.60 2.68 ± 0.81 0.003
APTT 32.17 ± 1.72 37.24 ± 3.29 0.001
WBCs 12.23 ± 1.93 12.96 ± 5.64 0.717
HB 99.83 ± 4.81 96.89 ± 3.69 0.120
Platelet 242.67 ± 111.86 173.33 ± 83.74 0.114
D-dimer 246.67 ± 62.78 504.44 ± 212.26 0.006
Na 140.50 ± 4.78 140.56 ± 0.53 0.962
K 3.85 ± 0.61 3.44 ± 0.27 0.025
Creatinine 71.17 ± 25.80 124.89 ± 41.08 0.000
Bilirubin 24.82 ± 11.13 24.24 ± 7.26 0.890
AST 30.33 ± 10.70 63.67 ± 35.53 0.023
ALT 41.83 ± 10.30 60.44 ± 31.52 0.119
GGT 50.83 ± 14.81 215.44 ± 325.28 0.168
Albumin 27.00 ± 2.59 26.67 ± 3.54 0.782
Fibrinogen 6.87 ± 1.46 7.74 ± 1.92 0.197
CRP 104.33 ± 95.04 135.11 ± 39.90 0.249
Effects of methyl prednisolone in early ARDS 169AST in the methyl prednisolone group 7 days from the date of
mechanical ventilation when compared to the control group.
And there was a signiﬁcant increase of PaCO2 in the control
group (see Table 2).
There were signiﬁcant improvements of pulse, systolic BP,
FIO2, peep, RR, O2sat, lactate, creatinine, WBCs, AST,
GGT, CRP, and CX-ray, with earlier extubation from
mechanical ventilation and improvement of mortality in the
methyl prednisolone group when compared with the control
group at the end of study, and there were signiﬁcant decreases
of protein C and protein S in the control group (see Table 3).There were signiﬁcant improvements of pulse, temperature,
systolic BP, FIO2, peep, RR, ps, O2sat, PaO2, PH, INR,
APTT, lactate, WBCs, platelets, creatinine, bilirubin, AST,
ALT, GGT, ﬁbrinogen, and CRP in the methyl prednisolone
group at the beginning of study and 7 days later (see Table 4).
There were signiﬁcant improvements of pulse, temperature,
systolic BP, FIO2, peep, RR, ps, O2sat, PaO2, INR, lactate,
WBCs, platelets, creatinine, bilirubin, AST, ALT, GGT,
ﬁbrinogen, CRP, D-dimer, and CX-ray in the methyl prednis-
olone group at the beginning of study and at the end of study.
And the rate of infection increased signiﬁcantly in the control
group (see Table 5).
There were no signiﬁcant changes in the control group at
the beginning of study and 7 days later (see Table 6).
There were signiﬁcant decreases of temperature, HB, pro-
tein C and protein S in the control group pre and at end of
study (see Table 7).
Discussion
The American–European Consensus Conference deﬁnes
ARDS as: [8]
h Acute onset of respiratory symptoms
h Chest radiograph with bilateral inﬁltrates
h Pulmonary artery wedge pressure (PAWP) of less than
18 mmHg (indicating no evidence of left heart failure)
h ARDS: PaO2/FIO2 ratio <200 mmHg
Table 4 Methyl prednisolone group before and 7 days from
study.
Methyl prednisolone
group before
Methyl prednisolone
group 7 days
P value
Pulse 104.33 ± 17.99 92.50 ± 14.86 0.002
Temperature 37.92 ± 0.75 37.13 ± 0.62 0.000
Systolic BP 127.50 ± 17.64 148.17 ± 14.99 0.001
Diastolic BP 67.00 ± 6.70 71.00 ± 13.38 0.219
FIO2 91.67 ± 12.49 65.00 ± 11.50 0.000
PEEP 11.00 ± 3.14 8.67 ± 1.85 0.000
RR 16.33 ± 2.77 14.83 ± 1.72 0.000
PS 15.83 ± 1.92 14.17 ± 1.92 0.010
O2sat 95.17 ± 2.75 97.67 ± 1.85 0.000
PaO2 70.33 ± 10.23 84.50 ± 9.08 0.000
PaCO2 31.05 ± 18.72 27.35 ± 16.26 0.045
PH 7.32 ± 0.03 7.35 ± 0.01 0.006
INR 1.37 ± 0.13 1.20 ± 0.10 0.000
Lactate 3.40 ± 2.11 1.78 ± 0.60 0.001
Aptt 34.67 ± 4.89 32.17 ± 1.72 0.049
WBCs 18.32 ± 2.68 12.23 ± 1.93 0.000
HB 90.33 ± 19.39 99.83 ± 4.81 0.088
Platelet 178.00 ± 106.19 242.67 ± 111.86 0.004
b 140.17 ± 5.77 140.50 ± 4.78 0.871
K 3.92 ± 0.81 3.85 ± 0.61 0.798
Creatinine 98.33 ± 54.29 71.17 ± 25.80 0.002
Bilirubin 35.12 ± 9.07 24.82 ± 11.13 0.000
AST 46.83 ± 31.83 30.33 ± 10.70 0.038
ALT 73.17 ± 27.77 41.83 ± 10.30 0.000
GGT 90.33 ± 58.62 50.83 ± 14.81 0.002
Albumin 27.00 ± 8.63 27.00 ± 2.59 1.000
Fibrinogen 9.20 ± 1.97 6.87 ± 1.46 0.000
CRP 240.67 ± 98.87 104.33 ± 95.04 0.000
Table 3 Clinical data, ventilator parameters, ABG, biochem-
ical examination and chest X-ray in methyl prednisolone group
and control group in 14th day of study.
Cases (n= 18) Control (n= 9) P value
Pulse 79.50 ± 7.85 98.89 ± 22.84 0.035
Temperature 36.73 ± 0.38 36.63 ± 1.13 0.802
Systolic BP 140.83 ± 11.37 117.78 ± 24.76 0.025
Diastolic BP 69.67 ± 11.65 67.78 ± 6.18 0.655
FIO2 41.67 ± 3.83 71.11 ± 24.21 0.006
PEEP 6.17 ± 1.38 12.00 ± 3.08 0.000
RR 13.00 ± 1.03 16.89 ± 2.47 0.001
PS 11.67 ± 2.43 15.00 ± 0.00 0.000
O2sat 100.00 ± 0.00 94.78 ± 4.97 0.014
PaO2 108.20 ± 8.80 88.11 ± 34.63 0.123
PH 6.71 ± 1.54 7.18 ± 0.29 0.222
INR 1.10 ± 0.00 1.58 ± 0.75 0.093
Lactate 1.42 ± 0.45 3.58 ± 2.82 0.050
APTT 32.50 ± 0.79 35.62 ± 9.31 0.344
WBCs 8.60 ± 1.63 15.91 ± 9.16 0.044
HB 99.83 ± 9.46 95.56 ± 4.98 0.218
Platelet 284.50 ± 139.25 186.44 ± 98.90 0.072
Na 136.33 ± 4.63 145.89 ± 3.14 0.000
K 4.35 ± 0.57 4.11 ± 0.72 0.354
Creatinine 60.33 ± 20.13 173.56 ± 146.66 0.049
Bilirubin 19.72 ± 9.75 36.22 ± 29.12 0.133
AST 21.33 ± 5.72 60.00 ± 30.21 0.005
ALT 25.67 ± 10.66 58.22 ± 51.51 0.096
GGT 30.33 ± 9.83 126.22 ± 75.76 0.005
Albumin 28.33 ± 4.85 30.00 ± 4.18 0.388
Fibrinogen 5.45 ± 1.17 6.14 ± 4.11 0.632
CRP 36.50 ± 47.80 186.44 ± 188.26 0.045
CXR-after 1.17 ± 0.71 2.33 ± 1.12 0.003
Date of extubation 10.56 ± 4.41 20.33 ± 1.86 0.000
Protein C 99.56 ± 13.02 66.78 ± 38.92 0.036
Protein S 111.61 ± 18.39 74.33 ± 33.09 0.010
Mortality
Live 18 (100%) 6 (66.7%) 0.009
Death 0 (0%) 3 (33.3%)
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mation in the ﬁrst week of mechanical ventilation determines
the physiologic progression (resolving vs. unresolving) and
outcome of the disease. [2]
Glucocorticoid treatment-induced down-regulation of sys-
temic inﬂammation in ARDS is associated with a signiﬁcant
improvement in pulmonary and extrapulmonary organ dys-
function and a reduction in duration of mechanical ventilation
and ICU length of stay. [1]
We aimed in this study to evaluate the effect of methyl
prednisolone when used early in ARDS.
In this study we found no signiﬁcance difference between
methyl prednisolone group and control group before the intro-
duction of methyl prednisolone in relation to demographic
data, etiology of ARDS, co morbidity, chest X-ray and most
of clinical parameters, ventilator parameters, and biochemical
investigation and this mean that the both groups were
comparable.
After 7 days there were signiﬁcant improvements of clinical
parameters (pulse, temperature, and systolic blood pressure),
peep (one parameter from lung injury score), lactate, D-dimer,
and AST, and highly signiﬁcant improvement of creatinine inthe methyl prednisolone group when compared to the control
group. This agreed with (Meduri et al. [1]) who studied 91 pa-
tients with severe early ARDS (<72 h), 66% with sepsis. Patients
were randomized (2:1 fashion) to methylprednisolone infusion
(1 mg/kg/d) vs. placebo. The duration of treatment was up to
28 days and found patients with methyl prednisolone achieving
the primary end point of a 1-point reduction in LIS.
After 14 days from starting the treatment there were signif-
icant improvements of clinical parameters (pulse, and systolic
BP), ventilator parameters (FIO2, peep, and RR), systemic
inﬂammation markers organ functions (O2sat, lactate, creati-
nine, WBCs, AST, and GGT) and CRP. And a signiﬁcant
improvement of CX-ray, and earlier extubation from mechan-
ical ventilation and improvement of mortality in the methyl
prednisolone group when compared with the control group,
improvement of mortality reﬂection to improvement of clinical
status, oxygenation, inﬂammatory markers and early extuba-
tion of this group. And there were signiﬁcant decreases of pro-
tein C and protein S in the control group. This indicate worse
clinical outcomes, including death, fewer ventilator-free days,
and more non pulmonary organ failures in this group. [6]
In the methylprednisolone group after 7 days from the
beginning of the drug there were signiﬁcant improvements of
clinical parameters (pulse, temperature, and systolic BP),
ventilator parameters (FIO2, peep, RR, and ps), two parame-
ters of three measured LIS (FIO2, PaO2, and peep) and sys-
temic inﬂammatory markers (CRP and organ functions).
And on day 14 in the same group there were signiﬁcant
improvements continued of the same parameters mentioned
Table 5 Methyl prednisolone group before and 14 days from
study.
Methyl prednisolone
group before
Methyl prednisolone
group 14 days
P value
Pulse 104.33 ± 17.99 79.50 ± 7.85 0.000
Temperature 37.92 ± 0.75 36.73 ± 0.38 0.000
Systolic BP 127.50 ± 17.64 140.83 ± 11.37 0.002
Diastolic BP 67.00 ± 6.70 69.67 ± 11.65 0.417
FIO2 91.67 ± 12.49 41.67 ± 3.83 0.000
PEEP 11.00 ± 3.14 6.17 ± 1.38 0.000
RR 16.33 ± 2.77 13.00 ± 1.03 0.000
PS 15.83 ± 1.92 11.67 ± 2.43 0.000
O2sat 95.17 ± 2.75 100.00 ± 0.00 0.000
PaO2 70.33 ± 10.23 108.20 ± 8.80 0.000
PaCO2 31.05 ± 18.72 32.50 ± 13.14 0.669
PH 7.32 ± 0.03 6.71 ± 1.54 0.113
INR 1.37 ± 0.13 1.10 ± 0.00 0.000
Lactate 3.40 ± 2.11 1.42 ± 0.45 0.000
Aptt 34.67 ± 4.89 32.50 ± 0.79 0.077
WBCs 18.32 ± 2.68 8.60 ± 1.63 0.000
HB 90.33 ± 19.39 99.83 ± 9.46 0.130
Platelet 178.00 ± 106.19 284.50 ± 139.25 0.001
Na 140.17 ± 5.77 136.33 ± 4.63 0.029
K 3.92 ± 0.81 4.35 ± 0.57 0.075
Creatinine 98.33 ± 54.29 60.33 ± 20.13 0.001
Bilirubin 35.12 ± 9.07 19.72 ± 9.75 0.000
AST 46.83 ± 31.83 21.33 ± 5.72 0.004
ALT 73.17 ± 27.77 25.67 ± 10.66 0.000
GGT 90.33 ± 58.62 30.33 ± 9.83 0.001
Albumin 27.00 ± 8.63 28.33 ± 4.85 0.653
Fibrinogen 9.20 ± 1.97 5.45 ± 1.17 0.000
CRP 240.67 ± 98.87 36.50 ± 47.80 0.000
Protein C 100.28 ± 14.80 99.56 ± 13.02 0.507
Protein S 114.89 ± 18.79 112.61 ± 18.39 0.126
CXR_before 3.67 ± 0.49 1.17 ± 0.71 0.000
D-dimer 1 508.89 ± 100.99 246.67 ± 62.78 0.000
Infection on 28 days
0 18 (100%) 6 (66.7%) 0.009
1 0 (0%) 3 (33.3%)
Table 6 (continued)
Control group before Control group 7 days P value
Na 138.56 ± 3.81 140.56 ± 0.53 0.175
K 3.92 ± 1.34 3.44 ± 0.27 0.233
Creatinine 171.56 ± 52.26 124.89 ± 41.08 0.094
Bilirubin 29.60 ± 19.39 24.24 ± 7.26 0.342
AST 225.44 ± 219.67 63.67 ± 35.53 0.070
ALT 100.89 ± 79.21 60.44 ± 31.52 0.200
GGT 185.33 ± 217.77 215.44 ± 325.28 0.503
Albumin 27.44 ± 5.70 26.67 ± 3.54 0.589
Fibrinogen 7.09 ± 2.95 7.74 ± 1.92 0.527
CRP 216.67 ± 186.51 135.11 ± 39.90 0.190
Table 6 Control group before and 7 days from study.
Control group before Control group 7 days P value
Pulse 120.89 ± 20.00 113.11 ± 4.26 0.191
Temperature 38.53 ± 0.88 37.89 ± 0.33 0.084
Systolic BP 120.00 ± 20.62 122.22 ± 13.02 0.512
Diastolic BP 69.78 ± 12.10 65.56 ± 6.82 0.385
FIO2 77.78 ± 22.79 64.44 ± 15.09 0.162
PEEP 8.44 ± 2.55 10.22 ± 1.20 0.117
RR 14.89 ± 2.85 16.44 ± 1.67 0.133
PS 13.33 ± 2.50 13.78 ± 1.92 0.169
O2sat 97.78 ± 2.54 99.11 ± 1.76 0.316
PaO2 91.33 ± 19.30 83.78 ± 11.14 0.138
PaCO2 43.89 ± 6.43 49.22 ± 6.30 0.152
PH 7.18 ± 0.23 7.31 ± 0.07 0.074
INR 1.46 ± 0.43 1.39 ± 0.27 0.679
Lactate 2.24 ± 1.34 2.68 ± 0.81 0.343
Aptt 36.18 ± 4.56 37.24 ± 3.29 0.407
WBCs 17.60 ± 6.65 12.96 ± 5.64 0.106
HB 113.78 ± 18.69 96.89 ± 3.69 0.034
Platelet 224.89 ± 130.16 173.33 ± 83.74 0.039
Table 7 Control group before and 14 days from study.
Control group before Control group 14 days P value
Pulse 120.89 ± 20.00 98.89 ± 22.84 0.156
Temperature 38.53 ± 0.88 36.63 ± 1.13 0.000
Systolic BP 120.00 ± 20.62 117.78 ± 24.76 0.815
Diastolic BP 69.78 ± 12.10 67.78 ± 6.18 0.727
FIO2 77.78 ± 22.79 71.11 ± 24.21 0.650
PEEP 8.44 ± 2.55 12.00 ± 3.08 0.063
RR 14.89 ± 2.85 16.89 ± 2.47 0.217
PS 13.33 ± 2.50 15.00 ± 0.00 0.081
O2sat 97.78 ± 2.54 94.78 ± 4.97 0.227
PaO2 91.33 ± 19.30 88.11 ± 34.63 0.798
PaCO2 43.89 ± 6.43 53.22 ± 15.65 0.204
PH 7.18 ± 0.23 7.18 ± 0.29 0.983
INR 1.46 ± 0.43 1.58 ± 0.75 0.730
Lactate 2.24 ± 1.34 3.58 ± 2.82 0.260
Aptt 36.18 ± 4.56 35.62 ± 9.31 0.881
WBCs 17.60 ± 6.65 15.91 ± 9.16 0.710
HB 113.78 ± 18.69 95.56 ± 4.98 0.018
Platelet 224.89 ± 130.16 186.44 ± 98.90 0.478
Na 138.56 ± 3.81 145.89 ± 3.14 0.001
K 3.92 ± 1.34 4.11 ± 0.72 0.757
Creatinine 171.56 ± 52.26 173.56 ± 146.66 0.975
Bilirubin 29.60 ± 19.39 36.22 ± 29.12 0.589
AST 225.44 ± 219.67 60.00 ± 30.21 0.076
ALT 100.89 ± 79.21 58.22 ± 51.51 0.317
GGT 185.33 ± 217.77 126.22 ± 75.76 0.397
Albumin 27.44 ± 5.70 30.00 ± 4.18 0.400
Fibrinogen 7.09 ± 2.95 6.14 ± 4.11 0.657
CRP 216.67 ± 186.51 186.44 ± 188.26 0.777
Protein C 109.22 ± 17.48 66.78 ± 38.92 0.024
Protein S 120.00 ± 20.15 74.33 ± 33.09 0.015
CX-ray 3.11 ± 0.93 2.33 ± 1.12 0.244
D-dimer 444.44 ± 84.57 504.44 ± 212.26 0.481
Effects of methyl prednisolone in early ARDS 171before, CX-ray, and the incidence of infection was signiﬁcantly
lower in the same group. And this agreed with (Annane et al.
[7]) who conclude that Long course of low dose corticosteroids
reduced 28-day all-cause mortality, and intensive care unit and
hospital mortality, and decreased incidence of infection.
We conclude that methyl prednisolone when used on ﬁrst
2 days in ARDS patients improves the LIS, decreases the sys-
temic inﬂammation, earlier extubation from mechanical venti-
lation, and decreases the incidence of hospital acquired
infection.
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